Psychedelic Wellness


Early studies find psilocybin shows promise for some psychiatric disorders...

With numerous studies in stage 3 trials, the opportunities to leverage psilocybin for clinical care is likely to expand in the next few years. Matt Stang shares his excitement for the future of this agent as means to help more patients.

To learn more on psilocybin and earn CME credit, see Psilocybin Revisited: The Science Behind the Drug and Its Surprising Therapeutic Potential.

Mr Stang is the founder of Delic Corp.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.